Proventil HFA Inhalation Aerosol
The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Pulmonary/Respiratory Diseases
General Information
The approval of Proventil HFA (albuterol sulfate) Inhalation
Aerosol covers a supplemental new drug application that provides
for the following: lowering the age from 12 years to 4 years and
older for the treatment or prevention of
- bronchospasm with reversible obstructive airway disease
- exercise-induced bronchospasm
